471 related articles for article (PubMed ID: 29804834)
1. Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome.
Weinert BT; Narita T; Satpathy S; Srinivasan B; Hansen BK; Schölz C; Hamilton WB; Zucconi BE; Wang WW; Liu WR; Brickman JM; Kesicki EA; Lai A; Bromberg KD; Cole PA; Choudhary C
Cell; 2018 Jun; 174(1):231-244.e12. PubMed ID: 29804834
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
3. Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition.
Hogg SJ; Motorna O; Cluse LA; Johanson TM; Coughlan HD; Raviram R; Myers RM; Costacurta M; Todorovski I; Pijpers L; Bjelosevic S; Williams T; Huskins SN; Kearney CJ; Devlin JR; Fan Z; Jabbari JS; Martin BP; Fareh M; Kelly MJ; Dupéré-Richer D; Sandow JJ; Feran B; Knight D; Khong T; Spencer A; Harrison SJ; Gregory G; Wickramasinghe VO; Webb AI; Taberlay PC; Bromberg KD; Lai A; Papenfuss AT; Smyth GK; Allan RS; Licht JD; Landau DA; Abdel-Wahab O; Shortt J; Vervoort SJ; Johnstone RW
Mol Cell; 2021 May; 81(10):2183-2200.e13. PubMed ID: 34019788
[TBL] [Abstract][Full Text] [Related]
4. Dynamic acetylation of all lysine-4 trimethylated histone H3 is evolutionarily conserved and mediated by p300/CBP.
Crump NT; Hazzalin CA; Bowers EM; Alani RM; Cole PA; Mahadevan LC
Proc Natl Acad Sci U S A; 2011 May; 108(19):7814-9. PubMed ID: 21518915
[TBL] [Abstract][Full Text] [Related]
5. Current development of CBP/p300 inhibitors in the last decade.
He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
[TBL] [Abstract][Full Text] [Related]
6. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
[TBL] [Abstract][Full Text] [Related]
7. Enhancers are activated by p300/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release.
Narita T; Ito S; Higashijima Y; Chu WK; Neumann K; Walter J; Satpathy S; Liebner T; Hamilton WB; Maskey E; Prus G; Shibata M; Iesmantavicius V; Brickman JM; Anastassiadis K; Koseki H; Choudhary C
Mol Cell; 2021 May; 81(10):2166-2182.e6. PubMed ID: 33765415
[TBL] [Abstract][Full Text] [Related]
8. Another One (of the "Undruggable" Targets) Bites the Dust: Discovery of a Potent and Selective Inhibitor of the Histone Acetyl Transferase p300/CBP.
Kodadek T
Biochemistry; 2018 Feb; 57(6):899-900. PubMed ID: 29244478
[No Abstract] [Full Text] [Related]
9. Use of histone deacetylase inhibitors to examine the roles of bromodomain and histone acetylation in p300-dependent gene expression.
Chen J; Li Q
Methods Mol Biol; 2013; 977():353-7. PubMed ID: 23436376
[TBL] [Abstract][Full Text] [Related]
10. Is histone acetylation the most important physiological function for CBP and p300?
Bedford DC; Brindle PK
Aging (Albany NY); 2012 Apr; 4(4):247-55. PubMed ID: 22511639
[TBL] [Abstract][Full Text] [Related]
11. Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation.
Raisner R; Kharbanda S; Jin L; Jeng E; Chan E; Merchant M; Haverty PM; Bainer R; Cheung T; Arnott D; Flynn EM; Romero FA; Magnuson S; Gascoigne KE
Cell Rep; 2018 Aug; 24(7):1722-1729. PubMed ID: 30110629
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors.
Xiong Y; Zhang M; Li Y
Curr Med Chem; 2020; 27(33):5583-5598. PubMed ID: 31364510
[TBL] [Abstract][Full Text] [Related]
13. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation.
Jin Q; Yu LR; Wang L; Zhang Z; Kasper LH; Lee JE; Wang C; Brindle PK; Dent SY; Ge K
EMBO J; 2011 Jan; 30(2):249-62. PubMed ID: 21131905
[TBL] [Abstract][Full Text] [Related]
14. 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer.
Du C; Huang D; Peng Y; Yao Y; Zhao Y; Yang Y; Wang H; Cao L; Zhu WG; Gu J
Cancer Lett; 2017 Aug; 400():183-193. PubMed ID: 28465257
[TBL] [Abstract][Full Text] [Related]
15. Probing p300/CBP associated factor (PCAF)-dependent pathways with a small molecule inhibitor.
Modak R; Basha J; Bharathy N; Maity K; Mizar P; Bhat AV; Vasudevan M; Rao VK; Kok WK; Natesh N; Taneja R; Kundu TK
ACS Chem Biol; 2013; 8(6):1311-23. PubMed ID: 23570531
[TBL] [Abstract][Full Text] [Related]
16. Histone Acetyltransferases p300 and CBP Coordinate Distinct Chromatin Remodeling Programs in Vascular Smooth Muscle Plasticity.
Chakraborty R; Ostriker AC; Xie Y; Dave JM; Gamez-Mendez A; Chatterjee P; Abu Y; Valentine J; Lezon-Geyda K; Greif DM; Schulz VP; Gallagher PG; Sessa WC; Hwa J; Martin KA
Circulation; 2022 Jun; 145(23):1720-1737. PubMed ID: 35502657
[TBL] [Abstract][Full Text] [Related]
17. Acetyltransferases CBP/p300 Control Transcriptional Switch of β-Catenin and Stat1 Promoting Osteoblast Differentiation.
Zhang L; Zhu K; Xu J; Chen X; Sheng C; Zhang D; Yang Y; Sun L; Zhao H; Wang X; Tao B; Zhou L; Liu J
J Bone Miner Res; 2023 Dec; 38(12):1885-1899. PubMed ID: 37850815
[TBL] [Abstract][Full Text] [Related]
18. Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders.
Valor LM; Viosca J; Lopez-Atalaya JP; Barco A
Curr Pharm Des; 2013; 19(28):5051-64. PubMed ID: 23448461
[TBL] [Abstract][Full Text] [Related]
19. Lysine acetyltransferases cyclic adenosine monophosphate response element-binding binding protein and acetyltransferase p300 attenuate transcriptional activity of the mineralocorticoid receptor through its acetylation.
Seo M; Song M; Seok YM; Kang SH; Lee HA; Sohn UD; Kim IK
Clin Exp Pharmacol Physiol; 2015 May; 42(5):559-66. PubMed ID: 25707758
[TBL] [Abstract][Full Text] [Related]
20. Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene.
Shankaranarayanan P; Chaitidis P; Kühn H; Nigam S
J Biol Chem; 2001 Nov; 276(46):42753-60. PubMed ID: 11509556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
